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Abstract: The discordance between pre-clinical success and clinical failure of treatment options for
Duchenne Muscular Dystrophy (DMD) is significant. The termination of clinical trials investigating the
phosphodiesterase inhibitors, sildenafil and tadalafil (which prolong the second messenger molecule
of nitric oxide (NO) signaling), are prime examples of this. Both attenuated key dystrophic features in
the mdx mouse model of DMD yet failed to modulate primary outcomes in clinical settings. We have
previously attempted to modulate NO signaling via chronic nitrate supplementation of the mdx
mouse but failed to demonstrate beneficial modulation of key dystrophic features (i.e., metabolism).
Instead, we observed increased muscle damage and nitrosative stress which exacerbated MD. Here,
we highlight that acute nitrite treatment of human DMD myoblasts is also detrimental and suggest
strategies for moving forward with NO replacement therapy in DMD.
Keywords: Duchenne muscular dystrophy; metabolism; nitric oxide; nitrite; reactive oxygen
species; superoxide
1. Introduction
The failure of therapeutic candidates to translate from pre-clinical animal work to clinical trial
success is unfortunately a common occurrence. This is particularly true for the muscle wasting
condition, Duchenne Muscular Dystrophy (DMD), a rare and incurable disease that is fatal in all cases.
Gene and exon skipping therapies, which partially restore the ablated dystrophin protein back into
the muscle membrane, are the only curative options. However, therapeutic use is limited to those
with specific dystrophin gene mutations (for exon skipping) and long-term safety and efficacy is yet
to be established (for both therapies). Thus, new treatment options are crucial, particularly since
standard-of-care corticosteroid practice is associated with side-effects which limits clinical utility.
2. Main
Re-purposing drugs is of particular benefit for rare diseases such as DMD as it can expedite
new therapeutic options since it leverages off previous safety and tolerability trials in other diseases.
One example of re-purposed drugs for the treatment of DMD are the phosphodiesterase (PDE)
type 5 inhibitors, sildenafil and tadalafil, both commonly prescribed for erectile dysfunction [1].
PDE inhibition enhances blood flow by increasing the half-life of cyclic guanosine 3′,5′-monophosphate
(cGMP), the second messenger of nitric oxide (NO) [1]. Pre-clinically, these PDE5 inhibitors prevented
skeletal muscle fatigue, ischemia and damage in the dystrophin-deficient mdx mouse indicating
that manipulation of the NO pathway is beneficial to dystrophic muscles [2–7]. Clinically, however,
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both have failed to modify primary endpoint measures, being delayed loss of ambulation (tadalafil;
NCT01865084) [8] and improved cardiac function (sildenafil; NCT01168908) [9] in DMD patients,
resulting in the termination of both trials. Similarly, sildenafil had no effect in Becker Muscular
Dystrophy patients [9,10]. While there are no individualized data reported for the tadalafil trial
(NCT01865084), there was evidence of participant-specific responsivity in the sildenafil trial where
4/14 participants (29%) experienced worsening of cardiac function with sildenafil versus 1/8 (12.9%) on
placebo and the other 10/14 showed no response [9]. These data suggest that other factors interplay to
orchestrate the biological effects of enhanced NO signaling in DMD.
In skeletal muscle, NO, produced by neuronal nitric oxide synthase (nNOS), is a critical
signaling molecule that modulates key physiological processes including blood flow, contraction,
glucose uptake and metabolism, among others [7]. In dystrophic muscles, nNOS dissociates from
the sarcolemma resulting in its targeted degradation [11–13] and consequently, a diminished capacity
for NO generation [7,14,15]. Reduced NO bioavailability impairs many processes including glucose
metabolism [16]. This contributes to the global metabolic dysfunction (and reduced adenosine
triphosphate (ATP) production) observed in dystrophic muscles [17–19], which we postulate is a key
driver of dystrophic pathology since metabolic efficiency is essential for cell life [20]. This led us to
question whether normalizing NO levels could have therapeutic potential. Since stimulating nNOS
(i.e., with l-arginine supplementation [21,22]) to enhance endogenous NO generation is limited by the
lower native nNOS protein content in dystrophic muscles, we sought to increase NO availability through
nNOS-independent means. The nitrate-nitrite-NO pathway is an nNOS-independent mechanism that
expands the NO pool [23]. Commensal bacteria reduce nitrate to nitrite (NIT), which is enzymatically
converted in the blood/tissues to NO [23]. Nitrate supplementation improves mitochondrial efficiency
and ATP production in healthy individuals [24], key parameters, which if improved, should theoretically
mitigate the dystrophic condition.
In contrast to our hypothesis, in Timpani et al. we demonstrated that 8-week long treatment of
dystrophic mdx mice with 1 mM nitrate was deleterious rather than therapeutic [25]. Despite nitrate
increasing citrate synthase activity (a marker of mitochondrial density), it exacerbated mitochondrial
uncoupling, muscle damage and nitrotyrosine staining (peroxynitrite marker) in dystrophic muscle [25].
The reaction of NO with superoxide results in the highly reactive nitrogen species, peroxynitrite,
which damages proteins. While nitrate supplementation also increased peroxynitrite content in
healthy control muscles (82% vs. 2775% increase in untreated vs. nitrate supplemented muscles,
respectively), there was no evidence of concomitant muscle damage as was seen in dystrophic
muscles [25]. This strain-dependent effect reflects the well-documented oxidative stress in dystrophic
mdx muscles [26,27] and highlights that uncontrolled NO generation within a pro-oxidant environment
exacerbates muscle damage. It is interesting to speculate whether variations in dietary antioxidant
intake or endogenous antioxidant responsivity could explain why some patients experienced worsening
of cardiomyopathy while others did not in the sildenafil trial [9].
We postulated that the detrimental effect of nitrate supplementation in the mdx mouse might
be due to the chronic treatment period used. To test this hypothesis, here we cultured immortalized
human DMD (fascia-lata of a 10 year old male with an exon 52 deletion in the dystrophin gene) and
healthy control (CON; paraspinal muscle of a 12 year old female) myoblasts as described previously
by us [28] (supplementary information) with 1 mM NIT (nitrate cannot be converted to NIT in cell
models) for 24 h. Cells were grown in medium containing low glucose 199 media (1:5, Gibco 11150059;
purchased from ThermoFisher Scientific (Scoresby, Australia)), high glucose Dulbecco’s modified eagle
medium (DMEM; 4:5, Gibco 10566016), fetuin (25 µg/mL, Sigma Aldrich (Sydney, Australia) F2379),
human epidermal growth factor (5 ng/mL; Sigma Aldrich E9644), basic human fibroblast growth
factor (0.5 ng/mL, Sigma Aldrich F0291), insulin (5 µg/mL, Sigma Aldrich I5500), dexamethasone
(0.2 µg/mL, Sigma Aldrich D4902), gentamycin (50 µg/mL, Gibco 15750060) and fetal bovine serum
(20%, Bovogen Biologicals (East Keilor, Australia)). Cells were seeded at a confluency of ~10% in 75 cm2
flasks and passaged every 3 days and experiments were performed on undifferentiated myoblasts.
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Following NIT treatment, mitochondrial viability was determined as described previously [29] using
5000 cells per well and a positive control of FCCP and antimycin A (3 µM each) to dissipate the
inner mitochondrial membrane potential (∆Ψ). Mitochondrial respiratory function (including spare
respiratory capacity, ATP production and coupling efficiency) and extracellular acidification rate
(ECAR), a measure of anaerobic glycolysis, were determined using the Seahorse Bioscience XF24
Analyzer as described in [28] with some modifications. On gelatin-coated (0.5%) Seahorse XF24
cell culture V7 microplates, CON (25,000 cells per well) and DMD myoblasts (15,000 cells per well)
were seeded and treated with NIT. 24 h later, media was replaced with pre-warmed assay buffer
(DMEM XF assay media (Seahorse Bioscience (North Billerica, MA, USA), 102365-10), 25 mM glucose
and 1 mM sodium pyruvate; pH 7.4). To a pre-hydrated XF24 Sensor Cartridge, 50 µL of oligomycin
(final concentration of 3 µM), 55 µL of FCCP (final concentration of 3 µM) and 60 µL of antimycin A
and rotenone (final assay concentration of 1 µM and 2 µM, respectively) was added to ports A, B and C
respectively. Finally, mitochondrial superoxide production was measured as described in [28] using
antimycin A (3 µM) as a positive control to induce superoxide generation. Two-way ANOVA was used
to detect between genotype and treatment differences. When a main effect/interaction was detected,
unpaired T-tests were used to identify between group differences using SPSS (version 21; Armonk, NY,
USA). An α value of 0.05 was considered significant.
Despite acute NIT treatment increasing mitochondrial viability (p < 0.01 DMD NIT vs. DMD
untreated (UNTREAT); Figure 1A) and spare respiratory capacity (p < 0.05 DMD NIT vs. DMD
UNTREAT; Figure 1B), this did not translate to improvements in other key metabolic parameters.
In fact, acute NIT treatment exacerbated the repression of ATP production (p < 0.05 DMD NIT vs.
DMD UNTREAT; Figure 1C) and mitochondrial uncoupling (p < 0.001 DMD NIT vs. DMD UNSUPP;
Figure 1D) already evident in DMD myoblasts. While mitochondrial uncoupling could be considered
protective against oxidative stress, in DMD myoblasts it only caused severe impact to ATP synthesis
without any attenuation of mitochondrial superoxide, which was 83% higher in NIT-treated compared
to UNTREAT dystrophic myoblasts (p < 0.05 DMD NIT vs. DMD UNTREAT; Figure 1E). Interestingly,
though, mitochondrial superoxide content decreased with extended NIT treatment of 3 and 7 days in
DMD myoblasts (by 66% and 93%, respectively compared to levels detected at 24 h; data not shown).
Ostensibly, these data suggested to us induction of the endogenous antioxidant response to oxidative
stress sufficient to attenuate detectable superoxide, which is a time-dependent event. However,
when these data are considered in context of our data from nitrate-treated mdx mice, the attenuation of
detectable superoxide seems more likely due to the vigorous formation of peroxynitrite. Our data
demonstrate that amplifying NO bioavailability in an acute manner worsens the metabolic crisis in
DMD cells and drives oxidative and nitrosative stress.
Augmentation of the spare respiratory capacity reflects the known metabolic modulatory effects
of NO on glycolytic flux, observed here through NIT-stimulated ECAR (p < 0.05 DMD NIT vs.
DMD UNTREAT; Figure 1F,G). Activity of phosphofructokinase (PFK), the rate-limiting enzyme of
glycolysis, is reduced in DMD patients [30] which appears to be caused through loss of allosteric
control by nNOS/NO [16]. Our observation suggests that in DMD myoblasts, PFK is activated by
NIT-derived NO, which stimulates glycolytic flux and pyruvate shuttling into the mitochondria for the
stimulation and expansion of the mitochondria tricarboxylic acid (TCA/Krebs) cycle. The outcome is
a higher proton gradient across the inner mitochondrial membrane i.e., increased spare respiratory
capacity. Paradoxically, this did not result in greater ATP production but rather in proton leak
(most likely through uncoupling proteins) which consumes the proton gradient without ATP yield.
Thus, the NO-driven compensatory stimulation of glycolytic flux cannot overcome the mitochondrial
dysfunction to re-balance energy homeostasis in DMD myoblasts.
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Figure 1. Mitochondrial viability, functional indices and superoxide production and extracellular 
acidification rate (ECAR) of untreated (UNTREAT) and nitrite (NIT) treated control (CON) and 
Duchenne Muscular Dystrophy (DMD) myoblasts. Cells were treated for 24 h with 1mM NIT. 
Mitochondrial viability was reduced in DMD myoblasts compared to CON (p < 0.0001), but NIT 
supplementation increased this parameter in DMD myoblasts (p < 0.01; A). Spare respiratory capacity, 
adenosine triphosphate (ATP) production and coupling efficiency (mitochondrial functional indices) 
were determined using the Seahorse Bioscience XF24 Analyzer with data presented per 5000 
myoblasts due to different plating densities of CON and DMD myoblasts. While NIT increased the 
Figure 1. Mitochondrial viability, functional indices and superoxide production and extracellular
acidification rate (ECAR) of untreated (UNTREAT) and nitrite (NIT) treated control (CON) and
Duchenne Muscular Dystrophy (DMD) myoblasts. Cells were treated for 24 h with 1 mM NIT.
Mitochondrial viability was reduced in DMD myoblasts compared to CON (p < 0.0001), but NIT
supplementation increased this parameter in DMD myoblasts (p < 0.01; A). Spare respiratory capacity,
adenosine triphosphate (ATP) production and coupling efficiency (mitochondrial functional indices)
were determined using the Seahorse Bioscience XF24 Analyzer with data presented per 5000 myoblasts
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due to different plating densities of CON and DMD myoblasts. While NIT increased the spare
respiratory capacity in DMD myoblasts (p < 0.05; B), NIT further reduced ATP production (p < 0.05; C)
and coupling efficiency (p < 0.0001; D) in DMD myoblasts. ATP production and coupling efficiency
are already reduced in DMD myoblasts compared to CON (p < 0.0001). Mitochondrial superoxide
production was higher in DMD myoblasts compared to CON (p < 0.01; E) and NIT treatment increased
it in both CON and DMD myoblasts (p < 0.05). Extracellular acidification rate (ECAR), a metric
of glycolytic flux, was measured using the Seahorse Bioscience XF24 Analyzer concomitantly with
mitochondrial function. Basal ECAR (F) and maximal ECAR (G) were significantly higher in DMD
myoblasts compared to CON (p < 0.01 and p < 0.0001 respectively) and NIT further stimulated ECAR
in DMD myoblasts only (p < 0.05). Results are presented as mean ± standard error of the mean.
Mitochondrial viability and superoxide assays: n = 4 per group; Seahorse assays: n = 7–8 CON
UNTREAT, n = 6 CON NIT, n = 5 DMD UNTREAT, n = 5 DMD NIT.
While our research suggests that manipulation of NO (particularly by the nitrate-NIT-NO
pathway) is pernicious in dystrophic muscles, there does appear to be some merit in pursuing
this treatment avenue. We saw more centronucleated fibers in nitrate-treated dystrophic muscles
which suggests augmentation of muscle regeneration [25]. It stands to reason that if we could
exploit this beneficial aspect of NO donor therapy while concomitantly buffering superoxide to
prevent the oxidative/nitrosative damage elicited, then the true capacity for NO donor therapeutics
would be known. For example, when sildenafil is administered in conjunction with vitamin E
(a known free oxygen radical scavenger) in diabetic rats, vitamin E enhances the therapeutic effect of
sildenafil [31]. If such a molecule were available, it could restore mitochondrial ATP production and
energy homeostasis to lessen damage in the first place, but also facilitate regeneration to halt disease
progression. Alternatively, other endogenous NO-generating enzymes such as endothelial NOS (eNOS)
could be exploited to circumvent the loss of nNOS-mediated NO signaling and naturally elevate
NO signaling within the vicinity of skeletal muscle tissue at beneficial physiological concentrations.
For example, resveratrol treatment has been shown to increase eNOS expression [32] and skeletal
muscle capillarization and oxygenation through eNOS-dependent NO signaling [33], and in mdx mice
this leads to improved endurance [34] (Figure 2).Antioxidants 2020, 9, x FOR PEER REVIEW 6 of 9 
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this culminates in muscle damage and wasting which impairs function. (B) We have previously 
demonstrated that the use of chronic nitrate supplementation to increase the NO pool is detrimental 
in dystrophic murine muscle. The superfluous ROS reacts with the NO to produce peroxynitrite 
(ONOO–) which amplifies muscle damage. As such, manipulation of the nitrate-nitrite-NO pathway 
and NO donor/signal amplifier drugs are unfeasible as a treatment for DMD as they currently stand. 
(C) Since we observed that the increased muscle damage in dystrophic murine muscle was 
accompanied by markers of higher regenerative capacity (i.e., centronucleated muscle fibers), we 
postulate that a combination therapy/dual function small molecule which increases NO 
bioavailability while addressing the oxidative stress may be beneficial rather than damaging. (D) 
Alternatively, increasing endogenous NO signaling e.g., through endothelial NOS (eNOS) with 
compounds such as resveratrol could circumvent the loss of nNOS-mediated NO signaling and 
restore physiologically relevant NO levels to induce benefits such as enhanced capillarization and 
muscle oxygenation. Image created with BioRender.com. 
3. Conclusions 
Here, we present the contraindicative nature of enhancing NO bioavailability as a treatment for 
DMD. Our previous findings in nitrate-treated mdx mice indicate that chronic NO (via nitrate) 
supplementation promotes nitrosative stress and muscle damage while here, acute NO (via NIT) 
supplementation of immortalized myoblasts derived from a DMD patient amplifies metabolic 
perturbations (with a flow on escalation of nitrosative stress likely). Taken with the failed clinical 
trials using PDE5 inhibitors to prolong NO signaling, it seems that clinical success through NO 
manipulation is unlikely. However, rather than abandon NO as a treatment option for DMD, 
modifying our approach may be the key. We suggest that a combination therapy or dual function 
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(A) Dystrophic muscle is characterized by mitoc dria w ich produce elevated reactive oxygen
Antioxidants 2020, 9, 1268 6 of 8
species (ROS) and reduced adenosine triphosphate (ATP). Along with other pathological processes,
this culminates in muscle damage and wasting which impairs function. (B) We have previously
demonstrated that the use of chronic nitrate supplementation to increase the NO pool is detrimental in
dystrophic murine muscle. The superfluous ROS reacts with the NO to produce peroxynitrite (ONOO–)
which amplifies muscle damage. As such, manipulation of the nitrate-nitrite-NO pathway and NO
donor/signal amplifier drugs are unfeasible as a treatment for DMD as they currently stand. (C) Since we
observed that the increased muscle damage in dystrophic murine muscle was accompanied by markers
of higher regenerative capacity (i.e., centronucleated muscle fibers), we postulate that a combination
therapy/dual function small molecule which increases NO bioavailability while addressing the oxidative
stress may be beneficial rather than damaging. (D) Alternatively, increasing endogenous NO signaling
e.g., through endothelial NOS (eNOS) with compounds such as resveratrol could circumvent the loss of
nNOS-mediated NO signaling and restore physiologically relevant NO levels to induce benefits such
as enhanced capillarization and muscle oxygenation. Image created with BioRender.com.
3. Conclusions
Here, we present the contraindicative nature of enhancing NO bioavailability as a treatment
for DMD. Our previous findings in nitrate-treated mdx mice indicate that chronic NO (via nitrate)
supplementation promotes nitrosative stress and muscle damage while here, acute NO (via NIT)
supplementation of immortalized myoblasts derived from a DMD patient amplifies metabolic
perturbations (with a flow on escalation of nitrosative stress likely). Taken with the failed clinical trials
using PDE5 inhibitors to prolong NO signaling, it seems that clinical success through NO manipulation
is unlikely. However, rather than abandon NO as a treatment option for DMD, modifying our approach
may be the key. We suggest that a combination therapy or dual function small molecule, which increases
the NO pool while addressing the oxidative stress (i.e., antioxidative capacity), may prove successful
for the treatment of DMD (Figure 2). This should be tested in a human-based cell culture system
(such as immortalized myoblasts/tubes derived from patients) in the first instance, which may improve
translational outcomes over testing only in non-genetically and/or -phenotypically homologous
animal models.
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